Bulletin
Investor Alert

New York Markets Open in:

Turning Point Therapeutics Inc.

NAS: TPTX

GO
/marketstate/country/us

Before the Bell

 --Quotes are delayed by 20 min

Aug 8, 2022, 8:00 a.m.

/zigman2/quotes/211319679/composite

$

74.97

Change

0.00 0.00%

Volume

Volume 71

Quotes are delayed by 20 min

/zigman2/quotes/211319679/composite

Previous close

$ 74.97

$ 74.97

Change

-0.28 -0.37%

Day low

Day high

$74.95

$75.39

Open

52 week low

52 week high

$23.77

$82.20

Open

Insider Actions for Turning Point Therapeutics Inc.

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/31/2022 Steve M Sabus
SVP & Chief Commercial Officer
36,667   Award at $0 per share. 0
04/11/2022 Brian Sun
SVP & General Counsel
45,000   Award at $0 per share. 0
02/09/2022 Athena M. Countouriotis
President & CEO; Director
62,400   Award at $0 per share. 0
02/09/2022 Mohammad Hirmand
EVP & Chief Medical Officer
15,000   Award at $0 per share. 0
02/09/2022 Mohammad Hirmand
EVP & Chief Medical Officer
18,983   Award at $0 per share. 0
02/09/2022 Andrew Partridge
EVP & Chief Commercial Officer
16,283   Award at $0 per share. 0
02/09/2022 Paolo Tombesi
EVP & Chief Financial Officer
16,283   Award at $0 per share. 0
02/09/2022 Annette C. North
EVP & General Counsel
16,283   Award at $0 per share. 0
02/09/2022 Siegfried Reich
EVP & Chief Scientific Officer
13,567   Award at $0 per share. 0
02/09/2022 Athena M. Countouriotis
President & CEO; Director
2,971   Disposition at $36.3 per share. 107,847
02/09/2022 Mohammad Hirmand
EVP & Chief Medical Officer
669   Disposition at $36.3 per share. 24,284
02/09/2022 Andrew Partridge
EVP & Chief Commercial Officer
221   Disposition at $36.3 per share. 8,022
02/09/2022 Annette C. North
EVP & General Counsel
669   Disposition at $36.3 per share. 24,284
02/09/2022 Siegfried Reich
EVP & Chief Scientific Officer
397   Disposition at $36.3 per share. 14,411
08/30/2021 Annette C. North
EVP & General Counsel
10,000   Disposition at $80 per share. 800,000
08/30/2021 Annette C. North
EVP & General Counsel
10,000   Derivative/Non-derivative trans. at $17 per share. 170,000
07/26/2021 Paolo Tombesi
EVP & Chief Financial Officer
13,600   Award at $0 per share. 0
07/14/2021 Andrew Partridge
EVP & Chief Commercial Officer
1,869   Disposition at $74.9 per share. 139,988
06/21/2021 Mark J. Alles
Director
2,000   Acquisition at $81.34 per share. 162,680
06/15/2021 Annette C. North
EVP & General Counsel
6,634   Disposition at $77.82 per share. 516,257
06/15/2021 Annette C. North
EVP & General Counsel
2,700   Disposition at $77.37 per share. 208,899
06/15/2021 Annette C. North
EVP & General Counsel
5,666   Disposition at $75.94 per share. 430,276
06/15/2021 Annette C. North
EVP & General Counsel
15,000   Derivative/Non-derivative trans. at $17 per share. 255,000
05/06/2021 Annette C. North
EVP & General Counsel
5,882   Derivative/Non-derivative trans. at $17 per share. 99,994
03/23/2021 Brian L. Baker
SVP of Finance and Admin.
100   Disposition at $104.17 per share. 10,417
03/23/2021 Brian L. Baker
SVP of Finance and Admin.
3,890   Disposition at $102.84 per share. 400,047
03/23/2021 Brian L. Baker
SVP of Finance and Admin.
8,061   Disposition at $102.23 per share. 824,076
03/23/2021 Brian L. Baker
SVP of Finance and Admin.
5,010   Disposition at $100.98 per share. 505,909
03/23/2021 Brian L. Baker
SVP of Finance and Admin.
1,996   Disposition at $100.07 per share. 199,739
03/23/2021 Brian L. Baker
SVP of Finance and Admin.
4,459   Disposition at $98.76 per share. 440,370
03/23/2021 Brian L. Baker
SVP of Finance and Admin.
4,919   Disposition at $97.89 per share. 481,520
03/23/2021 Brian L. Baker
SVP of Finance and Admin.
10,688   Derivative/Non-derivative trans. at $7.43 per share. 79,411
03/23/2021 Brian L. Baker
SVP of Finance and Admin.
4,545   Derivative/Non-derivative trans. at $5.12 per share. 23,270
03/23/2021 Brian L. Baker
SVP of Finance and Admin.
1,298   Derivative/Non-derivative trans. at $3.2 per share. 4,153
03/23/2021 Brian L. Baker
SVP of Finance and Admin.
11,904   Derivative/Non-derivative trans. at $2.19 per share. 26,069

Transaction Summary

Total insider purchases and sales reported to the SEC

Timeframe Transactions Shares
Last 3 months
1 Purchases
0 Sales
36,667
0
Last 6 months
9 Purchases
5 Sales
240,466
4,927
Last 12 months
10 Purchases
6 Sales
250,466
14,927

Officers and Executives

Dr. Athena M. Countouriotis
President, Chief Executive Officer & Director
Ms. Miriam Cruz
Vice President-Clinical Operations
Mr. Paolo Tombesi
Executive VP, Chief Financial & Accounting Officer
Dr. Mohammad Hirmand
Chief Medical Officer & Executive Vice President
Mr. Ed Gemo
Chief Information Officer & Senior Vice President
Dr. Gavin Hirst
Chief Scientific Officer & VP-Chemistry
Dr. Naseem Zojwalla
Vice President-Clinical Development
Ms. Homa Yeganegi
Senior Vice President & Head-Medical Affairs
Mr. Andrew Partridge
Chief Commercial Officer & Executive VP
Dr. Kumar Srinivasan
Chief Business Officer
Mr. Raymond J. Furey
SVP-Chief Compliance Officer & General Counsel
Mr. Kyri van Hoose
Vice President-Accounting
Dr. Adam Levy
Senior VP-Communications & Investor Relations
Ms. Heather Adams
Vice President-Human Resources
Mr. Scott Lipman
Chief of Staff
Mr. Brian Sun
Senior Vice President & General Counsel
Dr. Naresh K. Nayyar
Vice President-Regulatory Affairs
Mr. Mark J. Alles
Chairman
Dr. Carol Giltner Gallagher
Independent Director
Mr. Garry Allen Nicholson
Independent Director
Ms. Barbara W. Bodem
Independent Director
Dr. Simeon J. George
Independent Non-Executive Director
Mr. Clarence Patrick Machado
Independent Director
Link to MarketWatch's Slice.